Pyrazolopyrimidines as inhibitors of cyclin dependent kinases.

A compound represented by the formula ** ** structural, or a pharmaceutically acceptable salt or solvate thereof, wherein: R is heteroaryl, wherein said heteroaryl can be unsubstituted or optionally independently substituted with one or more radicals which may be the same or different; each moiety being selected separately from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF3, OCF3, CN, -OR5, -NR5R6, -C (R4R5) n OR 5, -C (O2) R5, -C ( O) R5, -C (O) NR5R6, -SR6, -S (O2) R7, -S (O2) NR5R6, -N (R5) S (O2) R7, -N (R5) C (O) R7 and -N (R5) C (O) NR5R6; R2 is selected from the group consisting of R9, alkyl, alkynyl, aryl, heteroaryl, CF3, heterocyclylalkyl, alkynylalkyl, cycloalkyl, -C (O) OR4, alkyl substituted with 1-6 R9 groups which can be the same or different.